Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant stabilized rsv a prefusion f antigen + recombinant stabilized rsv b prefusion f antigen
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Recombinant stabilized rsv a prefusion f antigen + recombinant stabilized rsv b prefusion f antigen** is a bivalent recombinant protein subunit RSV vaccine marketed as **Abrysvo** and developed by **Pfizer**. It contains two stabilized prefusion forms of the respiratory syncytial virus fusion glycoprotein F, one derived from RSV subgroup A and one from subgroup B, designed to induce neutralizing antibodies against prefusion F and thereby prevent RSV-associated lower respiratory tract disease. The vaccine is used for prevention of RSV disease in older adults and in pregnant individuals to protect infants through passive maternal immunization.
- Brand names
- Abrysvo
- Other names
- recombinant stabilized rsv a prefusion f antigen + recombinant stabilized rsv b prefusion f antigenbivalent respiratory syncytial virus prefusion f vaccinersvpreF
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on recombinant stabilized rsv a prefusion f antigen + recombinant stabilized rsv b prefusion f antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant stabilized rsv a prefusion f antigen + recombinant stabilized rsv b prefusion f antigen.